1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Apolipoprotein

Apolipoprotein

Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III. Specific apolipoproteins function in the regulation of lipoprotein metabolism through their involvement in the transport and redistribution of lipids among various cells and tissues, through their role as cofactors for enzymes of lipid metabolism, or through their maintenance of the structure of the lipoprotein particles.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153491A
    Olezarsen sodium
    Inhibitor
    Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen sodium
  • HY-164740A
    Plozasiran sodium
    Inhibitor
    Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran sodium
  • HY-P6365B
    APP-018
    99.80%
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
    APP-018
  • HY-151123
    Pelacarsen
    Pelacarsen (AKCEA-APO(a)-LRx) is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability.
    Pelacarsen
  • HY-P6306A
    CS-6253 TFA
    Agonist 98.53%
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
    CS-6253 TFA
  • HY-RS00846
    APOC3 Human Pre-designed siRNA Set A
    Inhibitor

    APOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    APOC3 Human Pre-designed siRNA Set A
  • HY-P5169A
    LVGRQLEEFL (mouse) TFA
    98.20%
    LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
    LVGRQLEEFL (mouse) TFA
  • HY-RS00844
    APOC1 Human Pre-designed siRNA Set A

    APOC1 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    APOC1 siRNA-1: 5 nmol (HPLC)

    APOC1 siRNA-2: 5 nmol (HPLC)

    APOC1 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)

    APOC1 Human Pre-designed siRNA Set A
  • HY-147425
    Zerlasiran
    Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran
  • HY-153491
    Olezarsen
    Inhibitor
    Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen
  • HY-P6365A
    APL180
    APL180 (L-4F) is an apolipoprotein A-I mimic peptide, that improves the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in researches of cardiovascular diseases.
    APL180
  • HY-171464
    Lp(a)-IN-5
    Inhibitor
    Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
    Lp(a)-IN-5
  • HY-W778692
    1-Linoleoyl Glycerol-d5
    1-Linoleoyl Glycerol-d5 (1-Linoleoyl-rac-glycerol-d5; 1-Monolinolein-d5) is the deuterium labeled 1-Linoleoyl Glycerol (HY-111346). 1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
    1-Linoleoyl Glycerol-d<sub>5</sub>
  • HY-P5169
    LVGRQLEEFL (mouse)
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
    LVGRQLEEFL (mouse)
  • HY-169932
    APOL1-IN-2
    Inhibitor
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
    APOL1-IN-2
  • HY-13031
    GW 841819X
    Activator
    GW 841819X is a potent inducer of the ApoA1 report gene, with an EC170 of 0.22 µM, and its pIC50 for Brd2/3/4 is 5.9/6.2/6.3.
    GW 841819X
  • HY-169080
    ABCA1 inducer 1
    Inducer
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4.
    ABCA1 inducer 1
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
    Inhibitor
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
  • HY-164740
    Plozasiran
    Inhibitor
    Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran
  • HY-148647
    Mipomersen
    Inhibitor
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).
    Mipomersen

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.